evidence table
Lutein Memory Randomized Trial Evidence Table
Structured evidence table for Lutein Memory Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Lutein Memory Randomized Trial | Population-based cohorts such as the Framingham Eye Study, Beaver Dam Eye Study, Blue Mountains Eye Study, and Rotterdam Study have provided advanced AMD incidence and risk factors in 5-year intervals. | 4 | Mukherjee Souvick (2026) | A Datasheet for Age-Related Eye Disease Study 2 on the Database of Genotypes and Phenotypes |
| Lutein Memory Randomized Trial | It enrolled 4203 participants (mean age = 73.1 years; range 50–85) at high risk for late AMD, which is defined as having bilateral large drusen (≥125 μm) or large drusen in 1 eye with advanced AMD in the fellow eye. | 4 | Mukherjee Souvick (2026) | A Datasheet for Age-Related Eye Disease Study 2 on the Database of Genotypes and Phenotypes |
| Lutein Memory Randomized Trial | All AREDS2 participants were offered secondary randomization to test different zinc doses and the omission of β-carotene, which is associated with increased lung cancer risk in smokers. | 4 | Mukherjee Souvick (2026) | A Datasheet for Age-Related Eye Disease Study 2 on the Database of Genotypes and Phenotypes |
| Lutein Memory Randomized Trial | Age-related conditions such as age-related macular degeneration (AMD) and cataracts are leading causes of irreversible vision loss in the aging population.Age-related macular degeneration accounts for 8.7% of blindness globally, while cataracts are prevalent in the fifth and sixth decades of life.Wong et al.provides comprehensive data on global prevalence and disease burden projections of these diseases through 2040. | 4 | Mukherjee Souvick (2026) | A Datasheet for Age-Related Eye Disease Study 2 on the Database of Genotypes and Phenotypes |
Source documents